At least 3 of Glenmark lead molecules failed or got suspended in mid-stage trials in the recent months

Glenmark has a direct presence in the UK market with first these first products of its own livery

India's generic firm Glenmark has stopped selling codeine sulfate pills used to manage pain, following US FDA's directive to stop marketing the tablets that have not received FDA approval.

Glenmark Pharmaceuticals Ltd may sell a portion of its stake in generic unit Glenmark Generic to raise fund to service mounting debts, reports said.

Glenmark Pharma to raise Rs 12 billion (US$250 million) from overseas markets Indian firm Glenmark Pharmaceuticals is planning to raise about Rs 12 billion (US$250 million) from overseas markets or by private placement of shares, the company said in an official announcement. The Mumbai-based Glenmark would raise US$250 million by Global Depository Receipts, American Depository Receipts and Foreign Currency Convertible Bonds or by private placement of shares or by qualified institutional investors. Glenmark's shareholders have approved to raise US$250 million. Glenmarks share holders have also approved an option to raise an additional funds if the issue is oversubscribed, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange. Recently, Glenmark Pharmaceuticals reportedly raised Rs 413 crore ($85 million) from share sale to institutional investors. Glenmark sold 1.87 crore shares to large investors at Rs 221 per share. Last week, Glenmark Generics (GGL), a US subsidiary of Mumbai-India based Glenmark Phamaceuticals, received approval for its generic version of hypertension drug verapamil extended release tablets from US FDA. Glenmark received approvals for its abbreviated new drug application (ANDA) for verapamil 240mg  strength extended release tablets from US FDA. Glenmark’s Verapamil 240mg  extended release tablet is the generic equivalent of Knoll Pharma’s Isoptin SR tablets. Glenmark has also filed a number of ANDAs in the extended Release segment that are pending for approval with the US FDA, Mr Coughlin added. Glenmark is expected to start marketing verapamil SR on 240 mg in the US market immediately. Verapamil SR on 240 mg’s approval expands Glenmark’s current portfolio to a total of 49 generic products authorized for distribution in the US market. Glenmark currently has over 45 ANDA’s filed with the US FDA pending approval. Glenmark joined hands with Aurobindo in July to launch thier generic versions of hypertension drugs fosinopril sodium and hydrochlorothiazide – the therapeutic equivalent of Bristol-Myers Squibb’s Monopril-HCT – in the US market. Glenmark Generics Inc., which received the approval from US FDA to market fosinopril sodium and hydrochlorothiazide tablets, will market fosinopril sodium and hydrochlorothiazide (HCTZ) pills in both 10mg/12.5mg and 20mg/12.5mg strengths and are indicated for the treatment of hypertension. Glenmark’s fosinopril sodium and hydrochlorothiazide pills are the therapeutic equivalent (generic) of Bristol Myers Squibb’s Monopril-HCT. In August, Glenmark Pharmaceuticals and US partner Forest Laboratories said oglemilast – a drug they were developing to treat chronic obstructive pulmonary disease (COPD) failed in a mid-stage trial COPD has an estimated market worth about $5 billion. Glenmark and Forest said a Phase IIb study meant to determine the best appropriate dosing for the medicine did not show statistically significant results. Glenmark has two other drugs in mid-stage trials currently in development. One to treat Type II diabetes, and one for osteoarthritic pain, incontinence and neuropathic pain, according to the company’s website. Glenmark has got first-to-file status for Zetia, with the generic name Ezetimibe, Tarka (Trandolapril + Verapamil) and Cutivate (Fluticasone lotion). Glenmark Pharma is planning to set up an injectables facility to produce cancer drugs in Buenos Aires as part of the company’s programme to strengthen its presence in the fast-emerging LatAm markets. Glenmark has reportedly set its sight on the Latam region as the pharmaceutical markets in Brazil, Mexico, Chile, Venezuela and Peru are set grow at a higher speed compared to the stalling regulated markets in US and Europe. Indian firm Glenmark Pharmaceuticals is planning to raise about Rs 12 billion (US$250 million) from overseas markets or by private placement of shares, the company said in an official announcement.

Glenmark Generics (GGL), a US subsidiary of Mumbai-India based Glenmark Phamaceuticals, has received approval for its generic version of hypertension drug verapamil extended release tablets from US FDA.

Glenmark plans to produce cancer drugs from its injectable unit in Argentina

India's Glenmark and Aurobindo are set to launch thier generic versions of hypertension drugs fosinopril sodium and hydrochlorothiazide - the therapeutic equivalent of Bristol-Myers Squibb's Monopril-HCT - in the US market.

Glenmark Pharmaceuticals has received first-to-file status for three of its new drugs applications (ANDA) that have a combined revenue of more than 2 billion USD, The Economic Times has reported.

Medicis settled a similar patent dispute with Perrigo in April 2009.